Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian McCroskey

Vascular Surgery Overland Park, KS Medical Doctor

NPI 1407851066 CMS profile 245697

4801 College Blvd, Overland Park, KS 66211

Open in the dashboard

General payments

$35,451

271 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian McCroskey of Overland Park, KS is reported in the CMS Open Payments database as having received $35,451 across 271 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,930 6
2024 General $3,707 26
2023 General $2,890 33
2022 General $3,213 49
2021 General $1,710 45
2020 General $1,013 22
2019 General $19,988 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian McCroskey
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Brian McCroskey were reported at $2,930. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Brian McCroskey Vascular Surgery median Middle half National median
2019 $19,988 $796 $226–$2,363 $163
2020 $1,013 $348 $118–$1,110 $114
2021 $1,710 $471 $158–$1,421 $132
2022 $3,213 $725 $222–$2,183 $149
2023 $2,890 $836 $257–$2,440 $160
2024 $3,707 $909 $252–$2,619 $164
2025 $2,930 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $16,411 34 payments
  2. Medtronic, Inc. $4,854 65 payments
  3. AngioDynamics, Inc. $4,235 4 payments
  4. Silk Road Medical, Inc. $2,013 26 payments
  5. Boston Scientific Corporation $1,590 15 payments
  6. W. L. Gore & Associates, Inc. $1,570 21 payments
  7. Endologix, Inc. $1,283 6 payments
  8. Medtronic Vascular, Inc. $676 21 payments
  9. Janssen Pharmaceuticals, Inc $564 25 payments
  10. LeMaitre Vascular, Inc. $250 4 payments
  11. Other $2,003 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,780 233 payments
  2. Education $12,500 5 payments
  3. Travel and Lodging $5,969 30 payments
  4. Long term medical supply or device loan $4,193 2 payments
  5. Consulting Fee $9 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $16,411 34 payments
  2. VenaCure 1470 Pro Id $2,400 1 payment
  3. VENASEAL $1,821 17 payments
  4. VenaCure 1470 Pro Et $1,793 1 payment
  5. ENROUTE 0.014 Guidewire $1,264 11 payments
  6. ENROUTE Transcarotid Stent System $1,264 11 payments
  7. ENROUTE Transcarotid Neuroprotection System $1,264 11 payments
  8. ENHANCE Transcarotid Peripheral Access Kit $1,264 11 payments
  9. ENDURANT IIS $1,192 16 payments
  10. General Therapies $770 3 payments
  11. Other $11,899 218 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

17

Median for Vascular Surgery: 122

Drug cost

$154

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 17 $154

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$44,114

Medicare's payments for the services billed

Medicare patients

134

Average age 73

Services billed

314

68 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 40%
Ischemic heart disease 37%
Chronic kidney disease 34%
Depression 26%
Atrial fibrillation 22%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

271 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record